Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low affinity immunoglobulin gamma Fc region receptor III-A (CD16a)
- Target
- CD16a
- Molecular classification
- Receptor, Immunoglobulin superfamily, Transmembrane glycoprotein
01
Overview
Low affinity immunoglobulin gamma Fc region receptor III-A (CD16a) is a transmembrane glycoprotein expressed on NK cells, macrophages, and some monocytes. It binds to the Fc portion of IgG antibodies clustered on target cells, triggering antibody-dependent cellular cytotoxicity (ADCC) and other immune responses. Genetic polymorphisms, particularly F158/V158, affect IgG binding affinity and clinical efficacy of therapeutic antibodies. After activation, CD16a surface expression is downregulated through proteolytic shedding.
- Other names
- FCGR3AFcgammaRIIIAFc gamma receptor III-AImmunoglobulin G Fc Receptor III
02
Mechanism of action
Binds to the Fc portion of IgG antibodies, activating NK cells and macrophages to induce ADCC and phagocytosis.
03
Biological functions
Antibody-dependent cellular cytotoxicity (ADCC)Immune responsePhagocytosisRemoval of antigen-antibody complexesSignal transduction
04
Disease associations
CancerViral infections
05
Safety considerations
Excessive immune responsesADAM17-mediated shedding as a regulatory mechanism
06
Interacting drugs
Therapeutic monoclonal antibodies (e.g., afucosylated IgGs)
07
Biomarkers
F158/V158 polymorphism (influences IgG binding affinity and clinical efficacy)
Beyond the preview
Go deeper on Low affinity immunoglobulin gamma Fc region receptor III-A (CD16a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor III-A (CD16a).